Gaballa Khaled, Metwally Islam H, Refky Basel, Awny Shadi, Abdelkhalek Mohamed, Hamdy Mohamed
Surgical Oncology Department, Oncology Center, Mansoura University (OCMU), Geehan Street, Mansoura, 35516 Dakahlia Egypt.
Indian J Surg Oncol. 2022 Sep;13(3):453-458. doi: 10.1007/s13193-022-01503-z. Epub 2022 Jan 17.
Obesity has long been associated with endometrial cancer. However, there is a paucity of studies addressing the impact of morbid obesity in type II endometrial cancer on oncologic and surgical outcomes. In this study, the author retrospectively compared morbid to non-morbid obese in clinico-epidemiologic, surgical, and oncologic outcomes. Both groups were comparable as regards all clinico-epidemiologic parameters. Vaginal involvement, survival, and recurrence were also comparable between the 2 groups. Para-aortic adenopathy and treatment with preoperative therapy were the only significant predictors of DFS. Surgery is feasible with equivalent complications and oncologic outcomes in morbidly obese patients with type II endometrial cancer.
肥胖长期以来一直与子宫内膜癌相关。然而，针对病态肥胖对II型子宫内膜癌的肿瘤学和手术结局的影响的研究却很匮乏。在本研究中，作者回顾性比较了病态肥胖与非病态肥胖患者在临床流行病学、手术及肿瘤学结局方面的差异。两组在所有临床流行病学参数方面均具有可比性。两组之间的阴道受累情况、生存率及复发情况也具有可比性。腹主动脉旁淋巴结肿大及术前治疗是无病生存期（DFS）的唯一显著预测因素。对于患有II型子宫内膜癌的病态肥胖患者，手术是可行的，且并发症和肿瘤学结局相当。
